Expert opinion on the management of hepatitis C infection in Kuwait

References

• Mohd HanafiahKGroegerJFlaxmanADWiersmaSTGlobal epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalenceHepatology20135741333134223172780
   PubMed Web of Science ®Google Scholar
• Antiretroviral Therapy Cohort ColllaborationCauses of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studiesClin Infect Dis201050101387139620380565
   PubMed Web of Science ®Google Scholar
• DawMADauAAHepatitis C virus in Arab world: a state of concernScientificWorldJournal2012201271949422629189
   PubMed Web of Science ®Google Scholar
• AmeenRSanadNAl-ShemmariSPrevalence of viral markers among first-time Arab blood donors in KuwaitTransfusion200545121973198016371052
   PubMed Web of Science ®Google Scholar
• PacsaASAl-MuftiSChughTDGenotypes of hepatitis C virus in KuwaitMed Princ Pract2001105567
   Web of Science ®Google Scholar
• AASLD/IDSA HCV Guidance PanelHepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virusHepatology201562393295426111063
   PubMed Web of Science ®Google Scholar
• European Association for Study of LiverEASL recommendations on treatment of hepatitis C 2015J Hepatol201563119923625911336
   PubMed Web of Science ®Google Scholar
• European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del H. EASL-ALEH Clinical Practice Guidelines: noninvasive tests for evaluation of liver disease severity and prognosisJ Hepatol201563123726425911335
   PubMed Web of Science ®Google Scholar
• ChouRClarkECHelfand M;US. Preventive Services Task Force. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task ForceAnn Intern Med2004140646547915023713
   PubMed Web of Science ®Google Scholar
• WorkowskiKABolanGACenters for Disease Control and PreventionSexually transmitted diseases treatment guidelines, 2015MMWR Recomm Rep201564RR-031137
   PubMed Web of Science ®Google Scholar
• AlterMJKuhnertWLFinelliLCenters for Disease Control and PreventionGuidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and PreventionMMWR Recomm Rep200352RR-3CE11CE14
   Google Scholar
• Centers for Disease Control and PreventionTesting for HCV infection: an update of guidance for clinicians and laboratoriansMMWR Morb Mortal Wkly Rep2013621836236523657112
   PubMed Web of Science ®Google Scholar
• CoffinPOScottJDGoldenMRSullivanSDCost-effectiveness and population outcomes of general population screening for hepatitis CClin Infect Dis20125491259127122412061
   PubMed Web of Science ®Google Scholar
• FeldJJKowdleyKVCoakleyETreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirinN Engl J Med2014370171594160324720703
   PubMed Web of Science ®Google Scholar
• FerenciPBernsteinDLalezariJABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCVN Engl J Med2014370211983199224795200
   PubMed Web of Science ®Google Scholar
• A special meeting review edition: highlights in the treatment of hepatitis C virus from the 2014 liver meeting: a review of selected presentations. From the 2014 Liver Meeting November 7–11, 2014Gastroenterol Hepatol (N Y)20141012 Suppl 6119
   Google Scholar
• ZeuzemSJacobsonIMBaykalTRetreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirinN Engl J Med2014370171604161424720679
   PubMed Web of Science ®Google Scholar
• PoordadFHezodeCTrinhRABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosisN Engl J Med2014370211973198224725237
   PubMed Web of Science ®Google Scholar
• KowdleyKVGordonSCReddyKRLedipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosisN Engl J Med2014370201879188824720702
   PubMed Web of Science ®Google Scholar
• AfdhalNReddyKRNelsonDRLedipasvir and sofosbuvir for previously treated HCV genotype 1 infectionN Engl J Med2014370161483149324725238
   PubMed Web of Science ®Google Scholar
• ReddyKRBourliereMSulkowskiMLedipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysisHepatology2015621798625846144
   PubMed Web of Science ®Google Scholar
• SulkowskiMSGardinerDFRodriguez-TorresMDaclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infectionN Engl J Med2014370321122124428467
   PubMed Web of Science ®Google Scholar
• LawitzESulkowskiMSGhalibRSimeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to PEGylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyLancet201438499561756176525078309
   PubMed Web of Science ®Google Scholar
• SulkowskiMSVargasHEDi BisceglieAMEffectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infectionGastroenterology2016150241942926497081
   PubMed Web of Science ®Google Scholar
• KwoPGitlinNNahassRSimeprevir plus sofosbuvir (12 and 8 weeks) in HCV genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized studyHepatology201664237038026799692
   PubMed Web of Science ®Google Scholar
• LawitzEMatusowGDeJesusESimeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a Phase 3 study (OPTIMIST-2)Hepatology201664236036926704148
   PubMed Web of Science ®Google Scholar
• JacobsonIMDoreGJFosterGRSimeprevir with PEGylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trialLancet2014384994140341324907225
   PubMed Web of Science ®Google Scholar
• MannsMMarcellinPPoordadFSimeprevir with PEGylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trialLancet2014384994141442624907224
   PubMed Web of Science ®Google Scholar
• ReddyKRZeuzemSZoulimFSimeprevir versus telaprevir with PEGinterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trialLancet Infect Dis2015151273525482330
   PubMed Web of Science ®Google Scholar
• LawitzEMangiaAWylesDSofosbuvir for previously untreated chronic hepatitis C infectionN Engl J Med2013368201878188723607594
   PubMed Web of Science ®Google Scholar
• PearlmanBLEhlebenCPerrysMThe combination of simeprevir and sofosbuvir is more effective than that of PEGinterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child’s class A cirrhosisGastroenterology20151484762770.e2 quiz.e11–225557952
   PubMed Web of Science ®Google Scholar
• ZeuzemSAndreonePPolSTelaprevir for retreatment of HCV infectionN Engl J Med2011364252417242821696308
   PubMed Web of Science ®Google Scholar
• PoordadFMcConeJJrBaconBRBoceprevir for untreated chronic HCV genotype 1 infectionN Engl J Med2011364131195120621449783
   PubMed Web of Science ®Google Scholar
• BaconBRGordonSCLawitzEBoceprevir for previously treated chronic HCV genotype 1 infectionN Engl J Med2011364131207121721449784
   PubMed Web of Science ®Google Scholar
• AsselahTAGATE-I Study – Part I: OBV/PTV/r + RBV in genotype 4 with cirrhosis. Presented at EASL 2016J Hepatol201664Abs. SAT-278S827
   Google Scholar
• WakedIAGATE-II Study: OBV/PTV/r + RBV in genotype 4 Egyptian patients without or with cirrhosis. Presented at EASL 2016J Hepatol201664Abs. SAT-166S772
   Web of Science ®Google Scholar
• HezodeCAsselahTReddyKROmbitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trialLancet201538599862502250925837829
   PubMed Web of Science ®Google Scholar
• KohliAKapoorRSimsZLedipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort studyLancet Infect Dis20151591049105426187031
   PubMed Web of Science ®Google Scholar
• AbergelAMetivierSSamuelDLedipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infectionHepatology20166441049105627351341
   PubMed Web of Science ®Google Scholar
• FeldJJMorenoCTrinhRSustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeksJ Hepatol201664230130726476290
   PubMed Web of Science ®Google Scholar
• AndreonePColomboMGEnejosaJVABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infectionGastroenterology20141472359365.e110.3851/IMP303724818763
   PubMed Web of Science ®Google Scholar
• PoordadFSchiffERVierlingJMDaclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrenceHepatology20166351493150526754432
   PubMed Web of Science ®Google Scholar
• CharltonMEversonGTFlammSLLedipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver diseaseGastroenterology2015149364965925985734
   PubMed Web of Science ®Google Scholar
• MannsMSamuelDGaneEJLedipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trialLancet Infect Dis201616668569726907736
   PubMed Web of Science ®Google Scholar
• FontanaRJBrownRSJrMoreno-ZamoraADaclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infectionLiver Transpl201622444645826890629
   PubMed Web of Science ®Google Scholar
• WelzelTMReddyKRFlammSLOn-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trialAntivir Ther201621654154626891418
   PubMed Web of Science ®Google Scholar
• PockrosPJReddyKRMantryPSEfficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal diseaseGastroenterology201615071590159826976799
   PubMed Web of Science ®Google Scholar
• SaxenaVKoraishyFMSiseMESafety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with impaired renal functionLiver Int201636680781626923436
   PubMed Web of Science ®Google Scholar
• NazarioHENdunguMModiAASofosbuvir and simeprevir in hepatitis C genotype 1- patients with end-stage renal disease on hemodialysis or GFR <30mL/minLiver Int201636679880126583882
   PubMed Web of Science ®Google Scholar
• CasteraLSebastianiGLe BailBde LedinghenVCouzigouPAlbertiAProspective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis CJ Hepatol201052219119820006397
   PubMed Web of Science ®Google Scholar
• CoppolaNDe PascalisSPisaturoMSustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cellsJ Clin Virol201358474875024140030
   PubMed Web of Science ®Google Scholar
• AfdhalNHBaconBRPatelKAccuracy of FibroScan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter studyClin Gastroenterol Hepatol2015134772779.e1-325528010
   PubMed Web of Science ®Google Scholar
• OrtizVBerenguerMRayonJMCarrascoDBerenguerJContribution of obesity to hepatitis C-related fibrosis progressionAm J Gastroenterol20029792408241412358265
   PubMed Web of Science ®Google Scholar
• HoSBBrauNCheungRIntegrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuseClin Gastroenterol Hepatol201513112005201425724704
   PubMed Web of Science ®Google Scholar
• Vespasiani-GentilucciUGalatiGGalloPDe VincentisARivaEPicardiAHepatitis C treatment in the elderly: new possibilities and controversies towards interferon-free regimensWorld J Gastroenterol201521247412742626139987
   PubMed Web of Science ®Google Scholar
• CainelliFHepatitis C virus infection in the elderly: epidemiology, natural history and managementDrugs Aging200825191818184025
   PubMed Web of Science ®Google Scholar
• YounossiZMStepanovaMNaderFHenryLPatient-reported outcomes of elderly adults with chronic hepatitis C treated with interferon-and ribavirin-free regimensJ Am Geriatr Soc201664238639326825683
   PubMed Web of Science ®Google Scholar
• ElrazekAEAmerMHawaryBPrediction of HCV vertical transmission: what are factors should be optimized using data mining computational analysisLiver Int201737452953327125252
   PubMed Web of Science ®Google Scholar
• TovoPACalitriCScolfaroCGabianoCGarazzinoSVertically acquired hepatitis C virus infection: correlates of transmission and disease progressionWorld J Gastroenterol20162241382139226819507
   PubMed Web of Science ®Google Scholar
• PoliquinVYudinMHMurphyKEOkunNAntepartum screening for maternal infection and immune status: is it time to broaden our routine?J Obstet Gynaecol Can201537121118112126637086
   PubMedGoogle Scholar
• SperaAMEldinTKTosoneGOrlandoRAntiviral therapy for hepatitis C: has anything changed for pregnant/lactating women?World J Hepatol201681255756527134703
   PubMed Web of Science ®Google Scholar
• GranotESokalEMHepatitis C virus in children: deferring treatment in expectation of direct-acting antiviral agentsIsr Med Assoc J2015171170771126757569
   PubMed Web of Science ®Google Scholar
• JainSGoharkhayNSaadeGHankinsGDAndersonGDHepatitis C in pregnancyAm J Perinatol200724425125617447189
   PubMed Web of Science ®Google Scholar
• FloreaniAHepatitis C and pregnancyWorld J Gastroenterol201319406714672024187446
   PubMed Web of Science ®Google Scholar
• SpauldingACWeinbaumCMLauDTA framework for management of hepatitis C in prisonsAnn Intern Med20061441076276916702592
   PubMed Web of Science ®Google Scholar
• LarneySKopinskiHBeckwithCGIncidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysisHepatology20135841215122423504650
   PubMed Web of Science ®Google Scholar
• BateJPColmanAJFrostPJShawDRHarleyHAHigh prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis CJ Gastroenterol Hepatol20102571276128020594255
   PubMed Web of Science ®Google Scholar
• KimAYNagamiEHBirchCEBowenMJLauerGMMcGovernBHA simple strategy to identify acute hepatitis C virus infection among newly incarcerated injection drug usersHepatology201357394495223111904
   PubMed Web of Science ®Google Scholar
• HoferHWatkins-RiedelTJanataOSpontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral loadHepatology2003371606412500189
   PubMed Web of Science ®Google Scholar
• DoreGJHellardMMatthewsGVEffective treatment of injecting drug users with recently acquired hepatitis C virus infectionGastroenterology2010138112313519782085
   PubMed Web of Science ®Google Scholar
• GrebelyJMatthewsGVPetoumenosKDoreGJSpontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infectionJ Viral Hepat2010171289620051007
   PubMed Web of Science ®Google Scholar
• MartinNKVickermanPGrebelyJHepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antiviralsHepatology20135851598160923553643
   PubMed Web of Science ®Google Scholar
• AspinallEJCorsonSDoyleJSTreatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysisClin Infect Dis201357Suppl 2S80S8923884071
   PubMed Web of Science ®Google Scholar
• FragomeliVWeltmanMAddressing viral hepatitis in the opiate substitution setting: an integrated nursing model of careJ Gastroenterol Hepatol201530Suppl 2611
   Web of Science ®Google Scholar
• AroraSThorntonKMurataGOutcomes of treatment for hepatitis C virus infection by primary care providersN Engl J Med2011364232199220721631316
   PubMed Web of Science ®Google Scholar
• BakerDAlaviMErrattADelivery of treatment for hepatitis C virus infection in the primary care settingEur J Gastroenterol Hepatol20142691003100925051216
   PubMed Web of Science ®Google Scholar
• WadeAJMacdonaldDMDoyleJSThe cascade of care for an Australian community-based hepatitis C treatment servicePLoS One20151011e014277026562516
   PubMed Web of Science ®Google Scholar
• HoSBBräuNCheungRIntegrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuseClin Gastroenterol Hepatol2015131120052014.e1-325724704
   PubMed Web of Science ®Google Scholar
• National Health and Medical Research Council (NHMRC)Australian Guidelines to Reduce Health Risks from Drinking Alcohol2009 Available from: http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/ds10-alcohol.pdfAccessed February 2016
   Google Scholar